xrd-0394

XRD-0394 is a novel, potent, orally bioavailable small molecule that acts as a dual inhibitor of ataxia telangiectasia mutated kinase (ATM) and DNA-dependent protein kinase (DNA-PK). By selectively targeting and inhibiting these two key kinases involved in the DNA damage response pathway, XRD-0394 disrupts DNA repair mechanisms in tumor cells. This inhibition prevents activation of the DNA damage checkpoint and enhances tumor cell apoptosis, particularly when combined with therapeutic ionizing irradiation or radiotherapy. Preclinical studies have shown that XRD-0394 significantly increases tumor cell kill *in vitro* and *in vivo* when used alongside radiation therapy. Additionally, it potentiates the effects of topoisomerase I inhibitors and shows synergy with PARP inhibitors—especially in BRCA1/2-deficient cells. The drug is being developed primarily for use as a radiosensitizer to improve outcomes for patients with metastatic, locally advanced, or recurrent solid tumors undergoing radiotherapy[1][2][3][5][7][8].

Other names

compound 569compound569compound-569